



EUROPEAN COMMISSION

Brussels, 23.10.2012  
C(2012)7621 final

**COMMISSION IMPLEMENTING DECISION**

**of 23.10.2012**

**amending the marketing authorisation granted by Decision C(2004)3580 for “Alimta -  
pemetrexed”, a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

## COMMISSION IMPLEMENTING DECISION

of 23.10.2012

**amending the marketing authorisation granted by Decision C(2004)3580 for  
“Alimta - pemetrexed”, a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE DUTCH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>1</sup>,

Having regard to Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products<sup>2</sup>, and in particular Article 17(2) thereof,

Having regard to the application submitted on 20 May 2012 by Eli Lilly Nederland B.V. under Article 16 of Regulation (EC) No 1234/2008,

Having regard to the opinion of the European Medicines Agency, formulated on 20 September 2012 by the Committee for Medicinal Products for Human Use,

Whereas:

- (1) The European Medicines Agency has informed the marketing authorisation holder and the Commission of its favourable opinion on the major variation type II and of the need to amend the marketing authorisation for the medicinal product "Alimta - pemetrexed" which is entered in the Community Register of Medicinal Products under numbers EU/1/04/290/001-002.
- (2) The marketing authorisation should be updated and Decision C(2004)3580 of 20 September 2004 should therefore be amended accordingly. The Community Register of Medicinal Products should also be updated.
- (3) For the sake of clarity and transparency, it is appropriate, following the amendment of part or parts of the Annexes, to provide for a consolidated version thereof. The Annexes to Decision C(2004)3580 should therefore be replaced,

---

<sup>1</sup> OJ L 136, 30.4.2004, p. 1.

<sup>2</sup> OJ L 334, 12.12.2008, p. 7.

HAS ADOPTED THIS DECISION:

*Article 1*

Decision C(2004)3580 is amended as follows:

Annex I is replaced by the text set out in the Annex I to this Decision.

*Article 2*

This Decision is addressed to Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA Houten, Nederland.

Done at Brussels, on 23.10.2012.

*For the Commission*  
*Paola TESTORI COGGI*  
*Director-General*